STIMのチャート
STIMの企業情報
| symbol | STIM |
|---|---|
| 会社名 | Neuronetics Inc （ニュ―ロネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 Neuronetics Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States. ニュ―ロネティクスは米国の医療機器メ―カ―。主に精神障害患者の生活の質を向上するための医療機器の開発・製造・販売に従事する。同社製品ニュ―ロスタ―・アドバンスト・セラピ―・システムは、うつ病患者の治療に対して非侵襲性で、パルスMRI強度磁場を作り脳の特定領域を刺激する電流を誘導する。本社所在地はペンシルベニア州マルバ―ン。 Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Visit NeuroStar.com for safety information and indications for use. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance. |
| 本社所在地 | 3222 Phoenixville Pike Malvern PA 19355 USA |
| 代表者氏名 | Chris Thatcher クリス・サッチャー |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 610-640-4202 |
| 設立年月日 | 37712 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.neuronetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/stim |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -16.16300 |
| 終値（lastsale） | 27.02 |
| 時価総額（marketcap） | 474931809.94 |
| 時価総額 | 時価総額（百万ドル） 409.89670 |
| 売上高 | 売上高（百万ドル） 46.00300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 614.37870 |
| 当期純利益 | 当期純利益（百万ドル） -21.67000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Neuronetics Inc revenues increased 31% to $23.4M. Net loss increased 76% to $13M. Revenues reflect United States segment increase of 30% to $22.9M International segment increase from $215K to $534K. Higher net loss reflects Sales and marketing - Balancing value increase of 41% to $17.8M (expense) General and administrative - Balancing increase of 65% to $5.6M (expense). |
STIMのテクニカル分析
STIMのニュース
Neuronetics Showcases New NeuroStar TMS Findings at Clinical TMS Society Annual Meeting 2023/05/03 12:58:00 Wallstreet:Online
Data highlights the Company’s commitment to advancing TMS and improving patient outcomes MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation
NeuroStar Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month 2023/05/02 13:01:00 Wallstreet:Online
Campaign features patients’ experiences to support others with depression A Media Snippet accompanying this announcement is available by clicking on the image or link below: MALVERN, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the
Neuronetics Inc. Appoints Lisa Metzner-Rosas as Chief Marketing Officer 2023/05/01 12:48:01 Investing.com
https://www.investing.com/news/assorted/neuronetics-inc-appoints-lisa-metznerrosas-as-chief-marketing-officer-432SI-3069039
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call 2023/04/25 12:30:00 GlobeNewswire
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Neuronetics Inc. Announces Expanded Health Insurance Coverage for TMS Therapy 2023/04/13 13:00:01 Investing.com
https://www.investing.com/news/assorted/neuronetics-inc-announces-expanded-health-insurance-coverage-for-tms-therapy-432SI-3054751
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 2022/08/05 20:30:00 GlobeNewswire
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to each employee''s entry into employment with the Company.
Neuronetics, Inc. (STIM) Q2 2022 Earnings Call Transcript 2022/08/03 02:30:53 The Motley Fool
STIM earnings call for the period ending June 30, 2022.
Neuronetics Inc (STIM) CEO Keith Sullivan on Q2 2022 Results - Earnings Call Transcript 2022/08/02 16:52:12 Seeking Alpha
Neuronetics Inc (NASDAQ:NASDAQ:STIM) Q2 2022 Earnings Conference Call August 2, 2022 08:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO…
Neuronetics, Inc. 2022 Q2 - Results - Earnings Call Presentation 2022/08/02 15:39:10 Seeking Alpha
The following slide deck was published by Neuronetics, Inc.
Recap: Neuronetics Q2 Earnings 2022/08/02 12:40:34 Benzinga
Neuronetics (NASDAQ: STIM ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Neuronetics beat estimated earnings by 4.88%, reporting an EPS of $-0.39 versus an … Full story available on Benzinga.com
A Quick Glance At Neuronetics Inc. (NASDAQ: STIM) Stock: It Is up 10.26% From Its 52-Week Low; YTD, It Is Down -30.04 Percent 2022/04/02 13:00:00 Marketing Sentinel
During the last session, Neuronetics Inc. (NASDAQ:STIM)’s traded shares were 0.34 million, with the beta value of the company hitting 2.36. At the end of the trading day, the stock’s price was $3.12, reflecting an intraday gain of 2.97% or $0.09. The 52-week high for the STIM share is $17.92, that puts it down -474.36 … A Quick Glance At Neuronetics Inc. (NASDAQ: STIM) Stock: It Is up 10.26% From Its 52-Week Low; YTD, It Is Down -30.04 Percent Read More »
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 2022/03/08 21:35:00 GlobeNewswire
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to five new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to each employee''s entry into employment with the Company.
Neuronetics, Inc. (STIM) Q4 2021 Earnings Call Transcript 2022/03/08 21:00:41 The Motley Fool
STIM earnings call for the period ending December 31, 2021.
Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales 2022/03/08 20:16:06 Benzinga
Neuronetics Inc (NASDAQ: STIM ) reported Q4 FY21 sales of $15.02 million , down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y due to lower NeuroStar Advanced Therapy System sales and treatment session … Full story available on Benzinga.com